How did AUTL's revenue and expenses trend in Q4 2024 compared to previous quarters?

Autolus Therapeutics PLC (AUTL) experienced a significant decline in revenue and an increase in expenses in Q4 2024 compared to the previous quarter, Q3 2024.

1. **Revenue Trend**: The company's revenue decreased by approximately 79.5% from Q3 2024 to Q4 2024. Specifically, the revenue in Q4 2024 was $2.065 million, while in Q3 2024, it was $10.09 million. This substantial drop indicates a challenging period for the company, especially considering the high expectations from the previous quarter.

2. **Expense Trend**: There are no available data on the exact expenses for Autolus Therapeutics in Q4 2024. However, the company's total operating expenses in Q3 2024 were $67.9 million. It is important to note that the company's net loss for Q3 2024 was $82.1 million, which was an increase from the previous quarter's net loss of $45.8 million. This suggests that while the revenue declined, the expenses, particularly the net loss, increased, indicating potential challenges in cost management.

In summary, Autolus Therapeutics faced a difficult quarter in Q4 2024, with a significant drop in revenue and an increase in net loss compared to the previous quarter, Q3 2024.